A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION
Stopped Overall clinical activity (ORR) for oleclumab + durvalumab is minimal across tumor types and does not support further evaluation of this doublet.
Conditions
- Non Small Cell Lung Cancer
- Renal Cell Carcinoma
Interventions
- BIOLOGICAL: Durvalumab
- BIOLOGICAL: Oleclumab
Sponsor
University Health Network, Toronto
Collaborators